I am a
Home I AM A Search Login

Papers of the Week

2022 Jun 25

Nephrol Dial Transplant

Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase III randomised controlled NOPHOS trial.


Ketteler M, Wiecek A, Rosenkranz AR, Ose C, Rekowski J, Lorenz H, Hellmann B, Karus M, Ruhmann M, Ammer R
Nephrol Dial Transplant. 2022 Jun 25.
PMID: 35751625.


We previously reported that modified-release nicotinamide (NAMR) was superior to placebo in reducing serum phosphate concentrations over 12 weeks in a large cohort of haemodialysis patients with hyperphosphataemia. Here, we report outcomes after 52 weeks of treatment.